PBC1
MCID: BLR024
MIFTS: 30

Biliary Cirrhosis, Primary, 1 (PBC1)

Categories: Endocrine diseases, Gastrointestinal diseases, Liver diseases

Aliases & Classifications for Biliary Cirrhosis, Primary, 1

MalaCards integrated aliases for Biliary Cirrhosis, Primary, 1:

Name: Biliary Cirrhosis, Primary, 1 57 13
Primary Biliary Cirrhosis 72
Pbc1 57
Pbc 57

Characteristics:

OMIM:

57
Inheritance:
autosomal dominant


HPO:

32
biliary cirrhosis, primary, 1:
Inheritance autosomal dominant inheritance


Classifications:



External Ids:

MedGen 42 C4551595
UMLS 72 C0008312

Summaries for Biliary Cirrhosis, Primary, 1

OMIM : 57 Primary biliary cirrhosis (PBC) is a chronic, progressive cholestatic liver disease that usually affects middle-aged women and eventually leads to liver failure (summary by Kaplan, 1996). (109720)

MalaCards based summary : Biliary Cirrhosis, Primary, 1, also known as primary biliary cirrhosis, is related to biliary cirrhosis, primary, 2 and reynolds syndrome. The drugs Abatacept and chenodeoxycholic acid have been mentioned in the context of this disorder. Affiliated tissues include liver, bone and b cells, and related phenotype is biliary cirrhosis.

Related Diseases for Biliary Cirrhosis, Primary, 1

Diseases in the Primary Biliary Cirrhosis family:

Biliary Cirrhosis, Primary, 1 Biliary Cirrhosis, Primary, 2
Biliary Cirrhosis, Primary, 3 Biliary Cirrhosis, Primary, 4
Biliary Cirrhosis, Primary, 5

Diseases related to Biliary Cirrhosis, Primary, 1 via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 76)
# Related Disease Score Top Affiliating Genes
1 biliary cirrhosis, primary, 2 11.6
2 reynolds syndrome 11.5
3 biliary cirrhosis, primary, 3 11.2
4 biliary cirrhosis, primary, 4 11.2
5 biliary cirrhosis, primary, 5 11.2
6 nodular regenerative hyperplasia 11.2
7 cholangitis 10.8
8 liver disease 10.6
9 autoimmune hepatitis 10.6
10 autoimmune disease 10.5
11 cholangitis, primary sclerosing 10.5
12 sclerosing cholangitis 10.5
13 varicose veins 10.4
14 scleroderma, familial progressive 10.4
15 raynaud phenomenon 10.4
16 portal hypertension 10.3
17 esophageal varix 10.3
18 telangiectasis 10.2
19 primary biliary cirrhosis 10.2
20 cholestasis 10.2
21 liver cirrhosis 10.2
22 primary biliary cholangitis 10.2
23 crest syndrome 10.2
24 viral hepatitis 10.2
25 systemic scleroderma 10.2
26 systemic lupus erythematosus 10.1
27 sjogren syndrome 10.1
28 cholangiocarcinoma 10.1
29 helix syndrome 10.1
30 calcinosis 10.1
31 intrahepatic cholangiocarcinoma 10.1
32 cytokine deficiency 10.1
33 pfeiffer syndrome 9.9
34 fibrosis of extraocular muscles, congenital, 1 9.9
35 myositis 9.9
36 osteoporosis 9.9
37 alkaline phosphatase, plasma level of, quantitative trait locus 1 9.9
38 sarcoidosis 1 9.9
39 thrombocytopenic purpura, autoimmune 9.9
40 trigeminal neuralgia 9.9
41 proteasome-associated autoinflammatory syndrome 1 9.9
42 alpha/beta t-cell lymphopenia with gamma/delta t-cell expansion, severe cytomegalovirus infection, and autoimmunity 9.9
43 bone mineral density quantitative trait locus 8 9.9
44 bone mineral density quantitative trait locus 15 9.9
45 graft-versus-host disease 9.9
46 leukemia, acute lymphoblastic 3 9.9
47 chlamydia pneumonia 9.9
48 inflammatory bowel disease 9.9
49 intrahepatic cholestasis of pregnancy 9.9
50 bone resorption disease 9.9

Graphical network of the top 20 diseases related to Biliary Cirrhosis, Primary, 1:



Diseases related to Biliary Cirrhosis, Primary, 1

Symptoms & Phenotypes for Biliary Cirrhosis, Primary, 1

Human phenotypes related to Biliary Cirrhosis, Primary, 1:

32
# Description HPO Frequency HPO Source Accession
1 biliary cirrhosis 32 HP:0002613

Symptoms via clinical synopsis from OMIM:

57
G I:
primary biliary cirrhosis

Lab:
impaired in vitro igg suppression

Clinical features from OMIM:

109720

Drugs & Therapeutics for Biliary Cirrhosis, Primary, 1

Drugs for Biliary Cirrhosis, Primary, 1 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 130)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Abatacept Approved Phase 4 332348-12-6 10237
2
chenodeoxycholic acid Approved Phase 4 474-25-9 10133
3
Sorafenib Approved, Investigational Phase 4 284461-73-0 216239 406563
4 Immunologic Factors Phase 4
5 Immunosuppressive Agents Phase 4
6 Antirheumatic Agents Phase 4
7 Gastrointestinal Agents Phase 4
8 Cathartics Phase 4
9 Laxatives Phase 4
10 Liver Extracts Phase 4
11 Protein Kinase Inhibitors Phase 4
12
Fenofibrate Approved Phase 3 49562-28-9 3339
13
Methotrexate Approved Phase 3 1959-05-2, 59-05-2 126941
14
leucovorin Approved Phase 3 58-05-9 143 6006
15
Lamivudine Approved, Investigational Phase 2, Phase 3 134678-17-4 60825
16
Zidovudine Approved Phase 2, Phase 3 30516-87-1 35370
17
Colchicine Approved Phase 3 64-86-8 6167 2833
18
Molybdenum Approved Phase 3 7439-98-7 185498
19
Copper Approved, Investigational Phase 3 7440-50-8 27099
20
Bezafibrate Approved, Investigational Phase 3 41859-67-0 39042
21
Atorvastatin Approved Phase 3 134523-00-5 60823
22
Metformin Approved Phase 2, Phase 3 657-24-9 4091 14219
23
Metronidazole Approved Phase 2, Phase 3 443-48-1 4173
24
Ursodeoxycholic acid Approved, Investigational Phase 3 128-13-2 31401
25
Budesonide Approved Phase 3 51333-22-3 63006 5281004
26
Folic acid Approved, Nutraceutical, Vet_approved Phase 3 59-30-3 6037
27
Taurochenodeoxycholic acid Experimental Phase 3 516-35-8 387316
28
Tauroursodeoxycholic acid Experimental, Investigational Phase 3 14605-22-2 12443252
29
Tetrathiomolybdate Investigational Phase 3 16330-92-0
30 Anti-Infective Agents Phase 3
31 Folic Acid Antagonists Phase 3
32 Folate Phase 3
33 Vitamin B Complex Phase 3
34 Vitamin B9 Phase 3
35 Dermatologic Agents Phase 3
36 Nucleic Acid Synthesis Inhibitors Phase 3
37 Antimetabolites, Antineoplastic Phase 3
38 Lamivudine, zidovudine drug combination Phase 2, Phase 3
39 Reverse Transcriptase Inhibitors Phase 2, Phase 3
40 Anti-HIV Agents Phase 2, Phase 3
41 Tubulin Modulators Phase 3
42 Antimitotic Agents Phase 3
43 Angiogenesis Inhibitors Phase 3
44 Angiogenesis Modulating Agents Phase 3
45 Chelating Agents Phase 3
46 Lipid Regulating Agents Phase 3
47 Hypolipidemic Agents Phase 3
48 Antimetabolites Phase 3
49 Hydroxymethylglutaryl-CoA Reductase Inhibitors Phase 3
50 Anticholesteremic Agents Phase 3

Interventional clinical trials:

(show top 50) (show all 96)
# Name Status NCT ID Phase Drugs
1 Double-blind, Double-dummy, Randomised, Crossover, Multicentre Phase IV Clinical Study Comparing the Effect of Ursofalk 500 mg Tablets od Versus Ursofalk 250 mg Capsules od on Liver Enzymes in the Treatment of Primary Biliary Cirrhosis Completed NCT01510860 Phase 4 UDCA (Ursodeoxycholic acid);UDCA (Ursodeoxycholic acid)
2 Abatacept For The Treatment Of Primary Biliary Cirrhosis With An Incomplete Biochemical Response To Ursodeoxycholic Acid Completed NCT02078882 Phase 4
3 Effectiveness of S-adenosyl-L-methionine in Patients With Primary Biliary Cirrhosis Completed NCT02557360 Phase 4
4 A Phase 4, Double-Blind, Randomized, Placebo-Controlled Study Evaluating the Pharmacokinetics and Safety of Obeticholic Acid in Patients With Primary Biliary Cholangitis and Moderate to Severe Hepatic Impairment Recruiting NCT03633227 Phase 4 Obeticholic Acid (OCA);Placebo
5 A Phase 4, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study Evaluating the Effect of Obeticholic Acid on Clinical Outcomes in Patients With Primary Biliary Cholangitis Recruiting NCT02308111 Phase 4 Obeticholic Acid (OCA);Placebo
6 Mechanism of Sorafenib Resistance in Patients With Advanced Hepatocellular Carcinoma Recruiting NCT02733809 Phase 4 Sorafenib
7 Fenofibrate in Combination With Ursodeoxycholic Acid in Primary Biliary Cirrhosis: a Randomized Control Study Unknown status NCT02823353 Phase 3 Fenofibrate;UDCA
8 Fenofibrate for Patients With Primary Biliary Cirrhosis Who Had An Inadequate Response to Ursodeoxycholic Acid Unknown status NCT02823366 Phase 3 Fenofibrate;UDCA
9 Fuzhenghuayu in Combination With Ursodeoxycholic Acid in Primary Biliary Cirrhosis Unknown status NCT02916290 Phase 3 Fuzhenghuayu;UDCA
10 Fuzhenghuayu for Patients With PBC Who Had An Inadequate Response to Ursodeoxycholic Acid Unknown status NCT02916641 Phase 3 Fuzhenghuayu;UDCA
11 Effectiveness of Ursodeoxycholic Acid Use in the Prevention of Gallstone Formation After Sleeve Gastrectomy: A Prospective Randomized Multicenter Placebo-Controlled Trial Unknown status NCT02721862 Phase 3 Ursodeoxycholic Acid;Placebo
12 A Phase 3, Double Blind, Placebo Controlled Trial and Long Term Safety Extension of Obeticholic Acid in Patients With Primary Biliary Cirrhosis Completed NCT01473524 Phase 3 Obeticholic Acid (OCA);Placebo
13 Phase III Randomized Study of Ursodiol With Vs Without Methotrexate for Primary Biliary Cirrhosis Completed NCT00004784 Phase 3 methotrexate;ursodiol
14 A Randomized, Double-blinded, Double-dummy, Parallel-controlled and Multicenter Clinical Trial to Investigate Safety and Efficacy of Tauroursodeoxycholic Acid Capsules in Treatment of Adult Primary Biliary Cirrhosis Completed NCT01857284 Phase 3 Tauroursodeoxycholic Acid Capsules;Ursodeoxycholic Acid Capsules
15 Randomized Controlled Pilot Study of Combivir for Patients With Primary Biliary Cirrhosis Completed NCT00490620 Phase 2, Phase 3 Combination antiviral therapy;Placebo
16 Safety and Efficacy of Long-Term Treatment With Atorvastatin in Patients With Primary Biliary Cirrhosis Completed NCT00844402 Phase 3 Atorvastatin
17 Phase III Randomized, Double-Blind, Placebo-Controlled Study of Low-Dose Oral Methotrexate Versus Colchicine for Primary Biliary Cirrhosis Completed NCT00004748 Phase 3 colchicine;methotrexate;ursodiol
18 Evaluate the Efficacy And Safety Of TUDCA Compare UDCA In The Treatment Of Cholestatic Liver Disease-PBC by A Randomized,Double-Blind,Double Dummy,Parallel-Controlled,Multicenter Trial and The Consecutive Treatment By TUDCA Completed NCT01829698 Phase 3 tauroursodeoxycholic;ursodeoxycholic acid
19 Ursodiol-Methotrexate for Primary Biliary Cirrhosis Completed NCT00006168 Phase 3 Methotrexate
20 Phase III Trial of Tetrathiomolybdate (TM) in Primary Biliary Cirrhosis Completed NCT00805805 Phase 3 Tetrathiomolybdate
21 Multicenter, Randomized, Double-blind Placebo Controlled Trial of Bezafibrate for the Treatment of Primary Biliary Cirrhosis in Patients With Incomplete Response to Ursodesoxycholic Acid Therapy. Completed NCT01654731 Phase 3 Bezafibrate;placebo
22 A Phase 3 Study to Evaluate the Place of Budesonide in the Treatment of GVHD Completed NCT00128739 Phase 3 Budesonide
23 Efficacy and Security of Bezafibrate in Patients With Primary Biliary Cirrhosis Without Biochemical Response to Ursodeoxycholic Acid: A Randomized, Double-blind, Placebo-controlled Trial Recruiting NCT02937012 Phase 3 Bezafibrate;Ursodeoxycholic Acid;Placebo (for Bezafibrate)
24 An Open Label Long-Term Study to Evaluate the Safety and Tolerability of Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) Recruiting NCT03301506 Phase 2, Phase 3 Seladelpar 2 mg Capsule;Seladelpar 5 mg Capsule;Seladelpar 10 mg Capsule
25 Estudio clínico Fase III Para Evaluar la Eficacia terapéutica en Pacientes Mexicanos Con Dislipidemia Mediante el Uso vía Oral de L-Carnitina + Atorvastatina Comparado Con Atorvastatina Active, not recruiting NCT03696940 Phase 3 L-Carnitine 500Mg Oral Tablet + Atorvastatin 10 mg;Atorvastatin 10mg
26 METformin in Intrahepatic Cholestasis of Pregnancy (METRIC) Study Not yet recruiting NCT03056274 Phase 2, Phase 3 Metformin;Ursodeoxycholic Acid
27 Double-blind, Randomised, Placebo-controlled, Multi-centre Phase III Clinical Study Comparing the Combination of Ursodeoxycholic Acid Capsules Plus Budesonide Capsules to Ursodeoxycholic Acid Capsules Plus Placebo in the Treatment of Primary Biliary Cirrhosis Terminated NCT00746486 Phase 3 budesonide;budesonide placebo
28 A Phase I/II, Open Label, Multicenter, Pilot Dose Escalation Study to Evaluate the Safety, Tolerability and Pharmacodynamics of FFP104 in Subjects Previously Diagnosed With Primary Biliary Cirrhosis (PBC) Unknown status NCT02193360 Phase 1, Phase 2 FFP104
29 Phase 1/2 Study of UC-MSC Treatment for Evaluation the Efficacy and Safety in Patients With Primary Biliary Cirrhosis Unknown status NCT01662973 Phase 1, Phase 2
30 Open-Labelled, Multicenter Phase II Study of Rituximab in Patients With Steroid-Refractory Chronic Graft-Versus-Host Disease Unknown status NCT00472225 Phase 2 Rituximab
31 A Randomized Controlled Clinical Trial on the Efficacy and Safety of Fenofibrate Combined With Ursodeoxycholic Acid in PBC Patients With an Incomplete Biochemical Response to UDCA Unknown status NCT02965911 Phase 1, Phase 2 Fenofibrate;UDCA
32 A Phase 2, Randomized, Double Blind, Placebo Controlled, Parallel Group, Multiple Center Study to Evaluate the Safety, Tolerability, and Pharmacodynamic Activity of NGM282 in Combination With Ursodeoxycholic Acid (UDCA) Administered for 28 Days in Patients With Primary Biliary Cirrhosis Completed NCT02026401 Phase 2
33 A Phase 2, Multi-Center Study to Evaluate Three Doses of NGM282 Administered for 24 Weeks in Patients With Primary Biliary Cirrhosis (PBC) Who Have Completed Study 13-0103 Completed NCT02135536 Phase 2
34 A Study of INT 747 (6α-ethyl Chenodeoxycholic Acid (6-ECDCA)) in Combination With Ursodeoxycholic Acid (URSO®, UDCA) in Patients With Primary Biliary Cirrhosis Completed NCT00550862 Phase 2 INT-747;Ursodeoxycholic Acid (URSO);Placebo
35 A Phase 2, Randomized, Double-blind, Placebo-controlled Study to Evaluate LUM001, an Apical Sodium-dependent Bile Acid Transporter Inhibitor (ASBTi) in Combination With Ursodeoxycholic Acid (UDCA) in Patients With Primary Biliary Cirrhosis Completed NCT01904058 Phase 2 LUM001;Placebo;Ursodeoxycholic Acid
36 Treatment of Cholestatic Pruritus With Sertraline Completed NCT00058903 Phase 2 sertraline
37 Pilot Study of Fenofibrate for Primary Biliary Cirrhosis Completed NCT00575042 Phase 2 Fenofibrate IDD-P (Insoluble Drug Delivery-Micro Particle)
38 A Study of INT-747 (6-ECDCA) Monotherapy in Patients With Primary Biliary Cirrhosis Completed NCT00570765 Phase 2 Placebo;INT-747;INT-747
39 A Pilot Study of Pentoxifylline for the Treatment of Primary Biliary Cirrhosis Completed NCT01249092 Phase 2 Pentoxifylline
40 Open-Label Pilot Investigation of Moexipril for the Treatment of Primary Biliary Cirrhosis (PBC) Completed NCT00588302 Phase 2 Moexipril
41 Effects of Rituximab (Rituxan) on B Cell and AMA Response in Patients With Primary Biliary Cirrhosis Completed NCT00364819 Phase 1, Phase 2 rituximab
42 A Phase 2 Clinical Trial Investigating the Effects of Obeticholic Acid on Lipoprotein Metabolism in Subjects With Primary Biliary Cirrhosis Completed NCT01865812 Phase 2 obeticholic acid (OCA)
43 A Phase 2, Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel-group Study Evaluating the Efficacy and Safety of Ustekinumab in Subjects With Primary Biliary Cirrhosis Who Had an Inadequate Response to Ursodeoxycholic Acid (UDCA) Completed NCT01389973 Phase 2 ustekinumab 90 mg;ustekinumab 45 mg;ustekinumab 180 mg;Placebo
44 A Randomised, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Repeat Doses of GSK2330672 Administration in Patients With Primary Biliary Cirrhosis (PBC) and Symptoms of Pruritus Completed NCT01899703 Phase 2 GSK2330672;Placebo;Ursodeoxycholic acid
45 A Multi-part, Randomized, Double-blind, Placebo-controlled Study to Assess the Safety, Tolerability and Efficacy of Tropifexor (LJN452) in Patients With Primary Biliary Cholangitis Completed NCT02516605 Phase 2 Part 1: LJN452;Part 1: Placebo;Part 2: LJN452 Dose level 1;Part 2: Placebo;Part 2: LJN452 Dose level 2
46 B-Cell Depleting Therapy (Rituximab) as a Treatment for Fatigue in Primary Biliary Cirrhosis Completed NCT02376335 Phase 2
47 Obeticholic Acid Treatment in Patients With Bile Acid Diarrhoea: an Open-label, Pilot Study of Mechanisms, Safety and Symptom Response. Completed NCT01585025 Phase 2 Obeticholic acid
48 A Phase 2, Prospective, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate Safety, Tolerability and Efficacy of Saroglitazar Magnesium in Patients With Primary Biliary Cholangitis (EPICS ) Recruiting NCT03112681 Phase 2 Saroglitazar magnesium 2 mg;Saroglitazar magnesium 4 mg;Placebo Oral Tablet
49 Safety and Efficacy of Human Unbilical Cord Derived-mesenchymal Stem Cells Treatment for Patients With Decompensated Liver Cirrhosis Recruiting NCT03945487 Phase 2
50 A Double-Blind, Randomized, Placebo-Controlled Clinical Trial to Assess the Efficacy and Safety of Oral GKT137831 in Patients With Primary Biliary Cholangitis Receiving Ursodeoxycholic Acid and With Persistently Elevated Alkaline Phosphatase Active, not recruiting NCT03226067 Phase 2 GKT137831;Placebo oral capsule

Search NIH Clinical Center for Biliary Cirrhosis, Primary, 1

Genetic Tests for Biliary Cirrhosis, Primary, 1

Anatomical Context for Biliary Cirrhosis, Primary, 1

MalaCards organs/tissues related to Biliary Cirrhosis, Primary, 1:

41
Liver, Bone, B Cells, Bone Marrow, Testes

Publications for Biliary Cirrhosis, Primary, 1

Articles related to Biliary Cirrhosis, Primary, 1:

(show all 46)
# Title Authors PMID Year
1
Dense fine-mapping study identifies new susceptibility loci for primary biliary cirrhosis. 8
22961000 2012
2
Variants at IRF5-TNPO3, 17q12-21 and MMEL1 are associated with primary biliary cirrhosis. 8
20639879 2010
3
Genome-wide meta-analyses identify three loci associated with primary biliary cirrhosis. 8
20639880 2010
4
Primary biliary cirrhosis associated with HLA, IL12A, and IL12RB2 variants. 8
19458352 2009
5
Identification of novel alleles at a polymorphic microsatellite repeat region in the human NRAMP1 gene promoter: analysis of allele frequencies in primary biliary cirrhosis. 8
10712108 2000
6
Primary biliary cirrhosis. 8
8900092 1996
7
Primary structure analysis and lamin B and DNA binding of human LBR, an integral protein of the nuclear envelope inner membrane. 8
8157662 1994
8
Familial primary biliary cirrhosis associated with impaired concanavalin A-induced lymphocyte transformation in relatives. Two family studies. 8
1735358 1992
9
Isolation and characterization of cDNA encoding a human nuclear antigen predominantly recognized by autoantibodies from patients with primary biliary cirrhosis. 8
2258622 1990
10
Identification and characterization of autoantibodies against the nuclear envelope lamin B receptor from patients with primary biliary cirrhosis. 8
2167346 1990
11
Primary structure of the human M2 mitochondrial autoantigen of primary biliary cirrhosis: dihydrolipoamide acetyltransferase. 8
3174635 1988
12
Coexistence of CREST syndrome and primary biliary cirrhosis. Serological studies of two cases. 8
3172118 1988
13
Genetic abnormalities of immunoregulation in primary biliary cirrhosis. 8
6222651 1983
14
Familial occurrence of primary biliary cirrhosis associated with hypergammaglobulinemia in descendants: a family study. 8
6965374 1980
15
Development of a Multiplex PCR Test System for the Determination of a Transgene Based on the pBC1 Plasmid and Its Derivatives for the Expression of Recombinant Proteins in Mus musculus Milk. 38
31201639 2019
16
Complete Genome Sequences of Bacillus Bacteriophages Wes44 and Carmen17. 38
30938704 2019
17
Odor mitigation and bacterial community dynamics in on-site biocovers at a sanitary landfill in South Korea. 38
29957505 2018
18
An AANAT/ASMT transgenic animal model constructed with CRISPR/Cas9 system serving as the mammary gland bioreactor to produce melatonin-enriched milk in sheep. 38
28273380 2017
19
A novel and highly specific phage endolysin cell wall binding domain for detection of Bacillus cereus. 38
26043681 2015
20
Bacteriophage PBC1 and its endolysin as an antimicrobial agent against Bacillus cereus. 38
25595773 2015
21
Validation of a recombinant human bactericidal/permeability-increasing protein (hBPI) expression vector using murine mammary gland tumor cells and the early development of hBPI transgenic goat embryos. 38
24289868 2013
22
Effective induction of pblac1 laccase by copper ion in Polyporus brumalis ibrc05015. 38
23332833 2013
23
Optimization of The Electroporation Conditions for Transfection of Human Factor IX into The Goat Fetal Fibroblasts. 38
23577306 2013
24
The construction and expression of lysine-rich gene in the mammary gland of transgenic mice. 38
22577831 2012
25
In vitro evaluation of a mammary gland specific expression vector encoding recombinant human lysozyme for development of transgenic dairy goat embryos. 38
22526423 2012
26
Complete genome sequence of Bacillus cereus bacteriophage PBC1. 38
22570248 2012
27
[Construction and identification of mammary expressional vector for cDNA of human lactoferrin]. 38
21650051 2011
28
Transient expression of chicken antimicrobial peptides by mouse mammary carcinoma cells C127. 38
20937033 2010
29
Development of a luciferase-based reporter system to monitor Bifidobacterium breve UCC2003 persistence in mice. 38
18816375 2008
30
Improved cloning vectors for bifidobacteria, based on the Bifidobacterium catenulatum pBC1 replicon. 38
18539807 2008
31
Functional analysis of the pBC1 replicon from Bifidobacterium catenulatum L48. 38
17704917 2007
32
Screening for plasmids among human bifidobacteria species: sequencing and analysis of pBC1 from Bifidobacterium catenulatum L48. 38
16930703 2007
33
Selection of donor nuclei in somatic cell-mediated gene transfer using a co-transfection method. 38
17077582 2007
34
Construct synthetic gene encoding artificial spider dragline silk protein and its expression in milk of transgenic mice. 38
17364439 2007
35
Molecular evidence that the extracellular cutinase Pbc1 is required for pathogenicity of Pyrenopeziza brassicae on oilseed rape. 38
12795380 2003
36
A cryptic plasmid, pAO1, from a compost bacterium, Bacillus sp. 38
11272838 2001
37
Transgenic Japanese lawngrass (Zoysia japonica Steud.) plants regenerated from protoplasts. 38
30736568 1998
38
Study of stability of recombinant plasmids during the continuous culture of Bacillus stearothermophilus NUB3621 in nonselective medium. 38
18634046 1997
39
Characterization, sequence and mode of replication of plasmid pNB2 from the thermophilic bacterium Clostridium thermosaccharolyticum. 38
9003300 1996
40
Updating prognosis in primary biliary cirrhosis using a time-dependent Cox regression model. PBC1 and PBC2 trial groups. 38
8253362 1993
41
Structural organization of a cryptic plasmid, pMA1, from Microcystis aeruginosa f. aeruginosa Kützing. 38
7764220 1993
42
Structural organization of pBC1, a cryptic plasmid from Bacillus coagulans. 38
1729254 1992
43
Stable transformation of sorghum cell cultures after bombardment with DNA-coated microprojectiles. 38
24221592 1991
44
Characterization of gram-positive broad host-range plasmids carrying a thermophilic replicon. 38
1908113 1991
45
Microelectrode assessment of chloride-conductive properties of cortical collecting duct. 38
6465322 1984
46
Plasmid transformation in Bacillus subtilis: effects of insertion of Bacillus subtilis DNA into plasmid pC194. 38
6267418 1981

Variations for Biliary Cirrhosis, Primary, 1

Expression for Biliary Cirrhosis, Primary, 1

Search GEO for disease gene expression data for Biliary Cirrhosis, Primary, 1.

Pathways for Biliary Cirrhosis, Primary, 1

GO Terms for Biliary Cirrhosis, Primary, 1

Sources for Biliary Cirrhosis, Primary, 1

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 TGDB
71 Tocris
72 UMLS
73 UMLS via Orphanet
Content
Loading form....